

## Supplementary Online Content

Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol*. Published online April 27, 2017. doi:10.1001/jamaoncol.2017.0589

**eTable 1.** Incidence of Neuroendocrine Tumors (NETs) Over Time

**eTable 2.** 10-Year and 20-Year Prevalence of NET

**eTable 3.** Median Survival of Distant Stage G1/G2 NETs Diagnosed From 2000-2012

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1. Incidence of Neuroendocrine Tumors (NETs) Over Time**

Registry	Year	Rate	Number of NET cases	Number at risk	Age specific incidence		
					less than 50	50-64 years	65 or older
SEER 9	1973	1.09	152	16,383,240	0.60	1.83	3.05
	1974	1.41	228	18,804,226	0.61	2.50	4.73
	1975	1.58	280	20,491,638	0.72	2.88	5.00
	1976	1.37	250	20,645,967	0.60	2.81	4.12
	1977	1.61	288	20,824,399	0.68	3.09	5.18
	1978	1.43	272	21,035,770	0.58	2.93	4.54
	1979	1.66	312	21,272,552	0.57	3.75	5.40
	1980	1.44	279	21,526,796	0.48	3.30	4.72
	1981	1.31	249	21,689,241	0.42	2.79	4.61
	1982	1.57	306	21,822,466	0.44	3.28	6.02
	1983	1.63	321	21,998,396	0.49	3.72	5.69
	1984	1.72	345	22,197,735	0.45	3.65	6.72
	1985	1.69	346	22,423,982	0.53	3.49	6.20
	1986	2.64	533	22,644,373	0.90	5.28	9.52
	1987	2.76	569	22,872,669	0.87	6.01	9.74
	1988	2.82	593	23,111,066	0.82	6.10	10.33
	1989	3.00	635	23,349,445	0.90	5.97	11.49
	1990	2.91	629	23,657,474	0.95	5.60	10.97
	1991	3.18	707	23,998,620	0.92	6.58	12.07
SEER 13	1992	3.21	1,016	35,796,360	0.88	6.68	12.38
	1993	3.32	1,070	36,209,880	0.92	7.02	12.65
	1994	3.42	1,116	36,515,300	0.97	6.98	13.23
	1995	3.96	1,299	36,853,744	0.89	8.78	15.81
	1996	4.12	1,372	37,247,652	1.05	8.93	16.02
	1997	4.29	1,456	37,697,798	1.11	8.73	17.24
	1998	4.73	1,631	38,144,594	1.12	9.30	19.98
	1999	4.76	1,671	38,555,266	1.06	10.93	18.62
	SEER 18	2000	4.90	3,613	78,996,813	1.24	10.60
2001		4.67	3,510	79,867,817	1.23	9.88	18.15
2002		5.14	3,947	80,629,975	1.29	11.56	19.57
2003		5.29	4,123	81,347,854	1.36	11.02	20.98
2004		5.44	4,335	82,055,585	1.39	12.08	20.79
2005		5.56	4,378	80,414,394	1.38	12.10	21.71
2006		5.94	4,880	83,099,557	1.46	12.69	23.62
2007		6.16	5,196	83,810,676	1.51	13.83	23.74
2008		6.27	5,401	84,618,783	1.54	14.34	23.79
2009		6.38	5,628	85,402,713	1.61	14.42	24.18
2010		6.57	5,913	86,156,841	1.68	14.53	25.11
2011		6.61	6,042	86,817,163	1.75	14.27	25.30

**eTable 2. 10-Year and 20-Year Prevalence of NET**

Year	20-year duration Prevalence	20-year Count	10-year duration Prevalence	10-year Count
1993	0.0060%	2,545		
1994	0.0111%	4,668		
1995	0.0157%	6,618		
1996	0.0196%	8,270		
1997	0.0233%	9,803		
1998	0.0265%	11,167		
1999	0.0294%	12,406		
2000	0.0321%	13,517		
2001	0.0345%	14,523		
2002	0.0367%	15,443		
2003	0.0384%	16,172	0.0061%	2,556
2004	0.0400%	16,864	0.0111%	4,694
2005	0.0415%	17,486	0.0158%	6,660
2006	0.0428%	18,016	0.0198%	8,323
2007	0.0439%	18,484	0.0234%	9,868
2008	0.0449%	18,920	0.0267%	11,241
2009	0.0458%	19,303	0.0296%	12,489
2010	0.0466%	19,626	0.0323%	13,607
2011	0.0473%	19,942	0.0347%	14,620
2012	0.0480%	20,233	0.0369%	15,542

\*all calculation are based on SEER 13. Prevalence date is Jan 1<sup>st</sup> of each year.

**eTable 3. Median Survival of Distant Stage G1/G2 NETs Diagnosed From 2000-2012**

Primary Tumor Site	Median Survival (months)	Survival Rate (%)	
		3-year	5-year
Appendix	NA	NA	NA
Cecum	98	70	61
Colon	14	33	29
Lung	24	39	32
Pancreas	60	62	50
Rectum	33	48	28
Small Intestine	103	80	69
Stomach	29	45	32

\*NA = not assessed due to small numbers